Jubilant Pharmova Limited
NSE: JUBLPHARMA
Employs 5,657 permanent employees and workers, 2.0% on the year before, as filed for the year to 31 Mar 2026 on a group basis. Revenue in the quarter to 31 Dec 2024 was ₹196 cr.
Headcount
Annual, from the BRSR filed with NSE (as of 31 March each year)
| As of | Scope | Permanent | Change (%) | Contract / other | Change (%) |
|---|---|---|---|---|---|
| 31 Mar 2023 | Group | 4,360 | — | 644 | — |
| 31 Mar 2024 | Group | 5,399 | 1,039(23.8%) | 351 | −293(45.5%) |
| 31 Mar 2025 | Group | 5,547 | 148(2.7%) | 542 | 191(54.4%) |
| 31 Mar 2026 | Group | 5,657 | 110(2.0%) | 729 | 187(34.5%) |
Permanent = permanent employees + permanent workers, as defined in SEBI's BRSR. "Standalone" figures cover the listed company alone and exclude its subsidiaries.
Financials (₹ cr)
| Period | Revenue (₹ cr) | Change (%) | Employee cost (₹ cr) | Change (%) | Net profit (₹ cr) | Change (%) | Flags |
|---|---|---|---|---|---|---|---|
| Quarter ended 31 Dec 2024 | 196 | 30(18.3%) | 52 | 1(1.4%) | 5 | −5(49.5%) | |
| Quarter ended 30 Sept 2024 | 166 | −1(0.6%) | 51 | 3(5.5%) | 11 | 21(202.9%) | |
| Quarter ended 30 Jun 2024 | 167 | −39(19.0%) | 49 | 2(4.7%) | -10 | −43(131.4%) | |
| Quarter ended 31 Mar 2024 | 206 | 31(17.5%) | 47 | −3(6.8%) | 33 | 35(1454.2%) | |
| Quarter ended 31 Dec 2023 | 175 | −11(6.0%) | 50 | 4(8.2%) | -2 | −2(500.0%) | |
| Quarter ended 30 Sept 2023 | 186 | −31(14.3%) | 46 | −1(2.9%) | -0 | −2(121.0%) | |
| Quarter ended 30 Jun 2023 | 217 | 18(8.8%) | 48 | 7(18.5%) | 2 | 33(106.2%) | |
| Quarter ended 31 Mar 2023 | 200 | 17(9.4%) | 40 | −3(6.6%) | -31 | −25(423.9%) | |
| Quarter ended 31 Dec 2022 | 183 | 154(534.7%) | 43 | 30(229.1%) | -6 | −3(89.4%) | ⚠ |
| Quarter ended 31 Mar 2022 | 29 | 10(54.2%) | 13 | −0(0.5%) | -3 | 2(41.8%) | ⚠ |
| Quarter ended 31 Dec 2021 | 19 | −1(6.8%) | 13 | 1(11.5%) | -5 | −93(106.1%) | ⚠ |
| Quarter ended 30 Sept 2021 | 20 | −0(1.1%) | 12 | 0(3.8%) | 88 | 89(7894.7%) | ⚠ |
| Quarter ended 30 Jun 2021 | 20 | −346(94.5%) | 11 | −23(67.5%) | -1 | −36(103.2%) | ⚠ |
| Quarter ended 31 Mar 2021 | 366 | — | 35 | — | 35 | — | ⚠ |